Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis.
Luciano M, Sieberer H, Krenn PW, Dang HH, Vetter J, Neuper T, Amend D, Blöchl C, Weichenberger CX, Eglseer A, Unger MS, Andosch A, Steiner P, Neureiter D, Bauer R, Hummer L, Tesanovic S, Binder S, Elmer DP, Strandt H, Schaller S, Strunk D, Pleyer L, Greil R, Winkler S, Hartmann TN, Schmidt-Arras D, Huber CG, Aberger F, Horejs-Hoeck J. Luciano M, et al. Among authors: neureiter d. Cell Commun Signal. 2024 Sep 2;22(1):424. doi: 10.1186/s12964-024-01777-6. Cell Commun Signal. 2024. PMID: 39223663 Free PMC article.
The Cdk inhibitor dinaciclib as a promising anti-tumorigenic agent in biliary tract cancer.
Ablinger C, Neureiter D, Mähr T, Mayr C, Kiesslich T, Maeding N, Valenta I, Ardelt M, Wilhelm F, Neureiter E, Ritter M, Pachmayr J, Huber-Cantonati P. Ablinger C, et al. Among authors: neureiter d. Cancer Biol Ther. 2024 Dec 31;25(1):2439057. doi: 10.1080/15384047.2024.2439057. Epub 2024 Dec 12. Cancer Biol Ther. 2024. PMID: 39668430 Free article.
New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et al.
Kiesslich T, Mayr C, Bekric D, Neureiter D. Kiesslich T, et al. Among authors: neureiter d. Transl Oncol. 2024 Jun;44:101820. doi: 10.1016/j.tranon.2023.101820. Epub 2023 Nov 15. Transl Oncol. 2024. PMID: 38641373 Free PMC article.
261 results